Upstate Active Clinical Trials

Study Title:

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

What is the purpose of the study? (in Layman's terms, please describe the study)

This study is being done to answer the following question: Can adding an immunotherapy drug (durvalumab) to usual chemotherapy before surgery lower the chance of breast cancer returning? We are doing this study because we want to find out if this approach is better, the same, or worse than the usual approach to treating HR- positive or HER2-negative breast cancer. The usual approach is defined as care most people get for HR+ and HER2- breast cancer.

Upstate Institutional Review Board (IRB) Number:

2153846

Study/Protocol ID:

S2206

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

What is involved if I participate?

• How long is the study?
  10 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  If you join the study, you will have more exams, tests, and procedures to closely monitor your safety and health.

Where will the study take place?

Upstate Cancer Center Medical Oncology main site, Community, Oswego, and Verona - all procedures

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT06058377

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Sienna Lee
Phone: 315-464-5934
Email: [email protected]

Return to Previous Page || Search Again